Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022:2390:483-501.
doi: 10.1007/978-1-0716-1787-8_22.

Artificial Intelligence in Drug Safety and Metabolism

Graham F Smith  1
Affiliations

Artificial Intelligence in Drug Safety and Metabolism

Graham F Smith. Methods Mol Biol. 2022.

Abstract

The use of artificial intelligence methods in drug safety began in the early 2000s with applications such as predicting bacterial mutagenicity and hERG inhibition. The field has been endlessly expanding ever since and the models have become more complex. These approaches are now integrated into molecule risk assessment processes along with in vitro and in vivo methods. Today, artificial intelligence can be used in every phase of drug discovery and development, from profiling chemical libraries in early discovery, to predicting off-target effects in the mid-discovery phase, to assessing potential mutagenic impurities in development and degradants as part of life cycle management. This chapter provides an overview of artificial intelligence in drug safety and describes its application throughout the entire discovery and development process.

Keywords: Applicability Domain; Artificial Intelligence; Cardiotoxicity; Computational Toxicology; DILI; Deep Learning; Digital Pathology; Drug Safety; Experimental Error; Genotoxicity; Hepatotoxicity; Machine Learning; Metabolism; Pharmacokinetics; Similarity; Structure Alerts.

PubMed Disclaimer

References

    1. DiMasi JA, Grabowski HG, Hansen RW (2016) Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ 47:20–33. https://doi.org/10.1016/j.jhealeco.2016.01.012 - DOI - PubMed
    1. Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3(8):711–715. https://doi.org/10.1038/nrd1470 - DOI - PubMed
    1. Hornberg JJ, Mow T (2014) How can we discover safer drugs? Future Med Chem 6(5):481–483. https://doi.org/10.4155/fmc.14.15 - DOI - PubMed
    1. Cook D, Brown D, Alexander R, March R, Morgan P, Satterthwaite G, Pangalos MN (2014) Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat Rev Drug Discov 13(6):419–431. https://doi.org/10.1038/nrd4309 - DOI - PubMed
    1. Morgan P, Brown DG, Lennard S, Anderton MJ, Barrett JC, Eriksson U, Fidock M, Hamren B, Johnson A, March RE, Matcham J, Mettetal J, Nicholls DJ, Platz S, Rees S, Snowden MA, Pangalos MN (2018) Impact of a five-dimensional framework on R&D productivity at AstraZeneca. Nat Rev Drug Discov 17(3):167–181. https://doi.org/10.1038/nrd.2017.244 - DOI - PubMed

Substances

LinkOut - more resources